MONDAY, Oct. 31 (HealthDay News) -- Exparel (bupivacaine
liposome injectable suspension) has been approved by the U.S. Food
and Drug Administration to treat post-surgical pain, maker Pacira
Pharmaceuticals said Monday.
The product combines the long-acting anesthetic bupivacaine with
Pacira's DepoFoam delivery technology. A single dose can provide
relief for up to 72 hours and reduce the need for opioid
painkillers, the drug maker said in a news release.
Exparel was evaluated in 21 clinical studies, including more
than 1,300 participants. The most common side effects reported
included nausea, constipation and vomiting, Pacira said.
The company is based in Parsippany, N.J.
To learn more about
pain, visit Medline Plus.